Liver Fat Stores Research Articles

The Effects of Resistance Training on Body and Liver Fat Stores and Insulin Resistance in Peoples with Non-Alcoholic Fatty Liver Disease

The article's abstract is no available.

Resistance training: the multifaceted side of exercise

to the editor: I read with great interest the article by Slentz et al. ([13][1]) titled “Effects of aerobic vs. resistance training on visceral and liver fat stores, liver enzymes, and insulin resistance by HOMA in overweight adults from STRRIDE AT/RT” published in the November 2011 issue of AJP

Effects of aerobic vs. resistance training on visceral and liver fat stores, liver enzymes, and insulin resistance by HOMA in overweight adults from STRRIDE AT/RT

While the benefits of exercise are clear, many unresolved issues surround the optimal exercise prescription. Many organizations recommend aerobic training (AT) and resistance training (RT), yet few studies have compared their effects alone or in combination. The purpose of this study, part of Studies Targeting Risk Reduction Interventions Through Defined Exercise-Aerobic Training and/or Resistance Training (STRRIDE/AT/RT), was to compare the effects of AT, RT, and the full combination (AT/RT) on central ectopic fat, liver enzymes, and fasting insulin resistance [homeostatic model assessment (HOMA)]. In a randomized trial, 249 subjects [18-70 yr old, overweight, sedentary, with moderate dyslipidemia (LDL cholesterol 130-190 mg/dl or HDL cholesterol ≤ 40 mg/dl for men or ≤ 45 mg/dl for women)] performed an initial 4-mo run-in period. Of these, 196 finished the run-in and were randomized into one of the following 8-mo exercise-training groups: 1) RT, which comprised 3 days/wk, 8 exercises, 3 sets/exercise, 8-12 repetitions/set, 2) AT, which was equivalent to ∼19.2 km/wk (12 miles/wk) at 75% peak O(2) uptake, and 3) full AT + full RT (AT/RT), with 155 subjects completing the intervention. The primary outcome variables were as follows: visceral and liver fat via CT, plasma liver enzymes, and HOMA. AT led to significant reductions in liver fat, visceral fat, alanine aminotransferase, HOMA, and total and subcutaneous abdominal fat (all P < 0.05). RT resulted in a decrease in subcutaneous abdominal fat (P < 0.05) but did not significantly improve the other variables. AT was more effective than RT at improving visceral fat, liver-to-spleen ratio, and total abdominal fat (all P < 0.05) and trended toward a greater reduction in liver fat score (P < 0.10). The effects of AT/RT were statistically indistinguishable from the effects of AT. These data show that, for overweight and obese individuals who want to reduce measures of visceral fat and fatty liver infiltration and improve HOMA and alanine aminotransferase, a moderate amount of aerobic exercise is the most time-efficient and effective exercise mode.

Abdominal adiposity and liver fat content 3 and 12 months after gastric banding surgery

Weight loss after laparoscopic adjustable gastric banding surgery (LAGB) is associated with mobilization of adipose tissue from a variety of depots. We sought to evaluate and relate abdominal and hepatic lipid deposition in an obese female population 3 and 12 months after LAGB. We related changes in these depots to markers of insulin sensitivity. Eighteen female obese subjects underwent magnetic resonance imaging and spectroscopy before and 3 and 12 months after LAGB for the quantification of abdominal subcutaneous (ABSAT) and visceral (VAT) adipose tissue areas and liver fat content (LFAT). Fasting blood free fatty acids (FFA) were analyzed. Insulin sensitivity was assessed by the homeostasis model assessment of insulin resistance index (HOMA-R). Mean weight loss 3 and 12 months after LAGB was 9.8 ± 1.1 kg and 20.0 ± 2.2 kg, respectively. Postoperatively, VAT area loss exceeded ABSAT area loss in the cohort as a whole and when divided according to preoperative liver fat stores. Three months after LAGB, reductions had occurred in VAT and ABSAT areas (both P < .01) and in FFA ( P < .05). Twelve months after LAGB, further significant reductions ( P < .01) occurred in VAT and ABSAT areas but not in FFA. No significant reduction occurred in LFAT at either time point in the group as a whole. In those with preoperative hepatic steatosis (LFAT >∼5%, n = 7), LFAT fell by 42% ( P = .036) 3 months after LAGB, with a total reduction of 50% ( P = .027 cf baseline) occurring by 12 months. There was an improvement in HOMA-R at 12 months (1.9 ± 0.3 cf 2.9 ± 0.5 at baseline, P = .04) but not 3 months (2.7 ± 0.4). Preoperatively, LFAT related significantly to VAT area ( r = 0.67, P = .003) and HOMA-R ( r = 0.497, P = .04) but not ABSAT area. Postoperatively at both 3 and 12 months, LFAT continued to relate to VAT area ( r = 0.63, P < .01 at both time points) but not HOMA-R. The changes in LFAT and VAT area were unrelated postoperatively. Abdominal adipose tissue loss was greater from the visceral than subcutaneous depots, suggesting that insulin sensitivity may not be an important determinant of selective lipid depot loss. The lack of a significant change in liver fat in the group as a whole may relate to low preoperative liver fat stores and to high postoperative dietary fat intakes. Preoperative liver fat stores did not influence insulin sensitivity or abdominal lipid changes during weight loss. Liver fat content and VAT area interrelated more closely than either related to ABSAT area, suggesting differing regulatory pathways for fat mobilization from ABSAT and VAT depots but possibly similar pathways for storage and mobilization of fat in the liver and viscerally.

ENHANCED LIVER-SPECIFIC FUNCTIONS BY COCULTIVATION OF IMMORTALIZED HUMAN HEPATOCYTES AND LIVER FAT-STORING CELLS

Purpose: Previously we have established a reversibly immortalized human hepatocyte cell line NKNT-3 to develop a bioartificial liver (BAL) (N. Kobayashi et al., Science 1252; 1246–1262, 2000). Preservation of differentiated hepatic phenotypes have an important application in BAL therapy. Hepatocyte viability and liver-specific functions have been shown to be stabilized for several weeks in vitro on cocultivation with liverfat storing cells (FSCs). Here we describe a method to expand the population of human FSCs for BAL treatment. Methods: Human fat-storing cells were transduced by a retroviral vector SSR#197 expressing the telomerase reverse transcriptase (hTERT) gene. One of immortalized FSCs with SSR#197, TWNT-1, was used in the present study based on the functional and proliferative characteristics. Differentiated liver functions were evaluated in a NKNT-3/TWNT-1 cell coculture system. Results: TWNT-1 cells showed the uptake of retinol and acetylated-LDL and synthesized collagen type 1. Cocultivation of immortalized hepatocytes NKNT-3 with TWNT-1 cells increased activities of P-450 isoenzymes 3A4 and 2C9 compared with a single culture of NKNT-3 cells. In addition, the amount of intracellular albumin and glycogen of NKNT-3 cells increased in a coculture condition. Conclusion: We have established highly differentiated immortalized human liver-fat storing TWNT-1 cells. Cocultivation of reversibly immortalized hepatocyte NKNT-3 and TWNT-1 cells could allow the development of a functional BAL.

Synthesis of cellular fibronectin by rat liver fat-storing (ito) cells: Regulation by cytokines

Fibronectins are multifunctional extracellular matrix glycoproteins that seem to play a pacemaker role in liver fibrogenesis. The expression of cellular fibronectin by rat liver fat-storing cells in primary culture and their modulation by cytokines was studied. Cellular fibronectin was localized in the cytoplasm and on the surface of cultured fat-storing cells as well as in extracellular matrix fibrils by indirect immunofluorescence. Immunoprecipitation of endogenously labeled fibronectin using type specific antibodies showed the synthesis and secretion of cellular fibronectin by fat-storing cells in vitro. ED1 positive sequences specific for cellular fibronectin and absent in plasma fibronectin were detected within the total RNA of fat-storing cells. Cellular fibronectin synthesis was severalfold enhanced in “activated” vs. “resting” fat-storing cells. Treatment of fat-storing cells with transforming growth factor β1 resulted in a dose dependent increase of fibronectin synthesis. In contrast, Interferon γ inhibited the synthesis of fibronectin. The stimulation of fibronectin synthesis by transforming growth factor β1 and the inhibition by Interferon γ might be of importance for pathophysiology and therapy of liver fibrogenesis.

Dexamethasone modulates α2-macroglobulin and apolipoprotein E gene expression in cultured rat liver fat-storing (Ito) cells

Fat-storing (Ito) cells are perisinusoidal liver cells thought to play a central role in vitamin A metabolism and fibrongenesis. Glucocorticoids have been shown to be beneficial in the treatment of certain types of liver diseases by delaying the development of cirrhosis. To study the regulatory effects of dexamethasone on Ito cell gene expression, Ito cells were isolated from normal rat liver and primary cultures were established. The effect of dexamethasone on the synthesis of alpha 2-macroglobulin, apolipoprotein E, fibronectin and actin was examined. Protein synthesis was studied both at the protein level and at the RNA level by means of biosynthetic labeling, immunoprecipitation followed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and by Northern blot analysis of total RNA. After exposure to dexamethasone for 20 hr, alpha 2-macroglobulin protein synthesis was increased threefold, whereas apolipoprotein E expression was decreased 80%. Biosynthesis of fibronectin remained unaffected by hormone treatment. The dexamethasone effect became detectable 5 hr after beginning the exposure. Deinduction kinetic experiments showed that the glucocorticoid effect was detectable more than 12 hr after the replacement of the dexamethasone-containing culture medium by medium without the hormone. Corresponding to the data obtained at the protein level, dexamethasone increased the steady-state levels of alpha 2-macroglobulin-specific messenger RNA and reduced apolipoprotein E-specific transcripts, whereas fibronectin and actin messenger mRNA remained unchanged.(ABSTRACT TRUNCATED AT 250 WORDS)

Time-Related Distribution Profiles of Sulfated Glycosaminoglycans in Cells, Cell Surfaces, and Media of Cultured Rat Liver Fat-Storing Cells

Fat-storing cells (perisinusoidal lipocytes, Ito cells), the principal proteoglycan-producing cell type in liver, were maintained for various times in primary and secondary culture to monitor the amount and pattern of [35S]sulfate-labeled glycosaminoglycans (GAG) in the cells, on the cell surface, and in the medium. In parallel with the phenotypic modulation of fat-storing cells toward myofibroblast-like cells, intracellular GAG decrease progressively, whereas cell surface-bound and medium GAG increase several-fold. These changes are associated with time-dependent alterations of the pattern of GAG in the various compartments. Dermatan sulfate is the most prominent intracellular GAG type in primary cultures, but on the cell surface and in the medium chondroitin sulfate prevails and reaches almost 70% of all medium GAG in secondary cultures. The results point to a highly dynamic expression of the specific types of GAG in the cellular and extracellular compartments of fat-storing cell cultures that seems to accompany the spontaneous transformation into myofibroblast-like cells. The latter one is a mainly chondroitin sulfate-producing cell type, whereas the initial fat-storing cell generates predominantly dermatan sulfate.

Synthesis and secretion of undulin by rat liver fat storing (ITO-) cells

Synthesis and secretion of undulin by rat liver fat storing (ITO-) cells

Secretion of Insulin-Like Growth Factor-I and Binding Proteins by Rat Liver Fat-Storing Cells: Regulatory Role of Platelet-Derived Growth Factor*

Insulin-like growth factor (IGF-I) is synthesized in multiple organs, including the liver, and may play a role in tissue growth and repair. We report that liver fat-storing cells (FSC) secrete IGF-I immunoreactivity in the culture medium. Secretion of IGF-I immunoreactivity was blocked in the presence of cycloheximide, suggesting de novo synthesis. Culture medium conditioned by FSC was concentrated and applied to a Sephadex G100 column equilibrated in a denaturing buffer. Two major species with apparent mol wts of 7.5 and greater than 25 k were identified by IGF-I RIA. Reverse phase HPLC of the 7.5 kilodalton species (the size of IGF-I) showed that it eluted in a single peak. To determine whether the higher mol wt species possessed IGF-I binding activity, appropriate fractions were desalted, incubated with [125I]IGF-I for 2 h at 30 C and applied to a Sephadex G100 column equilibrated in a nondissociating buffer. The major peak of radioactivity was confined to a high mol wt region. Western blot ligand analysis revealed the presence of two insulin-like growth factor binding proteins of approximately 28 and 31 kilodaltons. Platelet-derived growth factor, a potent mitogen for FSC, resulted in a 230% increase in release of IGF-I immunoreactivity that could be accounted for by an increase in IGF-I binding activity. In addition IGF-I increased DNA synthesis in FSC and this effect was additive to that of platelet-derived growth factor. IGF-I treatment also resulted in an increase in cell number. IGF-I and insulin-like growth factor binding proteins secreted by FSC may play a role in the hepatic tissue response to injury via autocrine and/or paracrine mechanisms.

Kupffer Cells from CC14-Treated Rat Livers Induce Skin Fibroblast and Liver Fat-Storing Cell Proliferation in Culture

Conditioned media of Kupffer cells from normal rat liver produce in culture two factors that inhibit fibroblast proliferation. The inhibitory factors have molecular masses of approximately 25 and 5 kDa. In contrasts to these results, the conditioned media of Kupffer and mononuclear macrophagic cells, obtained 48 hours after CC1(4) administration to rats, contains a 17 kDa factor that stimulates fibroblast proliferation (FSF). FSF also stimulates [3H]-thymidine incorporation into DNA of cultured rat liver fat-storing cells. Two peaks with FSF activity were demonstrated after isoelectrofocusing; one with a pI of 6.1 and a second with a pI of 7.5. The fraction containing FSF is devoid of interleukin-1 (IL-1) activity and no inhibitory activity is detected in this conditioned media. Production of FSF is inhibitable by colchicine but not by indomethacin, it is thermolabile and trypsin-sensitive. In animals treated chronically with CC1(4) to produce cirrhosis, FSF activity is demonstrable from the first to the 8th week of treatment. However, the activity is lower at 8 weeks post-CC1(4) as compared with 2 weeks. The results suggest that homeostasis of cells in the liver is controlled by factors produced locally, that act by autocrine and paracrine mechanisms. When homeostasis is altered, fibroblast proliferation occurs, and excess collagen deposition leads to fibrosis. We propose that the antifibrogenic activity of colchicine is associated, in part, with its capacity to inhibit the release of FSF by Kupffer cells and liver mononuclear macrophage cells.

The role of thrombocytes in liver fibrogenesis: effects of platelet lysate and thrombocyte-derived growth factors on the mitogenic activity and glycosaminoglycan synthesis of cultured rat liver fat storing cells.

A central problem in the study of the pathogenesis of liver fibrosis (fibrogenesis) is the identification of the cellular sources of the extracellular matrix and the dissection of the molecular mediators stimulating connective tissue synthesis in certain hepatic target cells. In the present study the role of platelets and of some platelet-derived polypeptide growth factors in the proliferation and proteoglycan synthesis of rat liver fat storing cells in culture (the principle connective tissue-producing cell type in liver) was determined. Fat storing cell proliferation was determined by measurement of the DNA-content, and [3H]thymidine- and bromodeoxyuridine-incorporation. Glycosaminoglycan synthesis was determined by the measurement of [35S]sulphate incorporation. Human platelet lysate (0.3 to 2.6 g protein per litre medium) stimulated, in a dose-dependent manner, both the proliferation and glycosaminoglycan synthesis of rat liver fat storing cells kept as a primary culture in Dulbecco's modification of Eagle's medium in the absence of foetal calf serum. More than 70% of the newly synthesized glycosaminoglycans were found in the medium. Among the various thrombocyte-derived polypeptides tested as candidate mediators of the platelet-derived fibrogenic activity, platelet derived growth factor was not effective in enhancing glycosaminoglycan synthesis, and it stimulated the proliferation of fat storing cells only about 2 fold. On the other hand, epidermal growth factor proved to be a stimulus of both processes. Transforming growth factor beta (greater than 10 pmol/l) inhibited foetal calf serum (Dulbecco's modification of Eagle's medium with a fraction of foetal calf serum of 0.1) and epidermal growth factor stimulated proliferation but enhanced the synthesis of sulphated glycosaminoglycans about 2-fold. These results suggest the possible role of transforming growth factor beta as a negative modulator for fat storing cells proliferation but a positive modulator for fat storing cell transformation and extracellular glycosaminoglycan matrix synthesis. Furthermore, our results indicate a cooperation between different hepatic and extrahepatic cell types by paracrine stimulation of fat storing cells. Transforming growth factor beta in combination with epidermal growth factor appear to be candidate mediators of the platelet-derived fibrogenic activity, which stimulates fat storing cells in culture, and might also be effective in vivo during hepatic repair processes following liver injury.

Hyaluronic acid synthesis and secretion by rat liver fat storing cells (perisinusoidal lipocytes) in culture

The ability of rat liver fat storing cells to synthesize and to secrete hyaluronic acid was examined in monolayer cultures. The cells produce [ 3H] glucosamine-labeled hyaluronic acid, of which about 80% are secreted into the medium. The synthesis rate per cell (mg DNA) of labeled total glycosaminoglycans and hyaluronic acid in the medium increases significantly with culture time, but hyaluronic acid expressed as fraction of total glycosaminoglycans declines from about 0.70 in early cultures (up to the 4th day) down to 0.20 in advanced cultures. Cycloheximide increases and β-D-xylopyranoside decreases significantly the fraction of hyaluronic acid in the medium, colchicine up to 5 uM was without effect. The synthesis of hyaluronic acid is a newly recognized function of this special type of sinusoidal liver cells. The results suggest that fat storing cells are likely to be a major source of hyaluronic acid in normal and probably also in injured liver.

Collagen production by rat liver fat-storing cells in primary culture.

Morphological changes, proliferation and collagen synthesis of fat-storing cells (FSC) in primary culture were examined. FSC, isolated from rats treated with vitamin A, showed numerous large lipid droplets in the cytoplasm and positive desmin staining. After 4-7 days culture, these cells were transformed into fibroblast-like cells with a gradual depletion of lipid droplets and with abundant well-developed rough endoplasmic reticulum. The proliferation analysis revealed that DNA synthesis preceded the increase of cell number. Enhancement of the collagen synthesis by FSC were associated with the morphological change of the cells. Quantitative analysis revealed that these cells produced mainly type I collagen (84%) and a small amount of type III collagen (16%).

Purified rat liver fat-storing cells in culture divide and contain collagen.

Primary cultures and cell lines were established from suspensions of purified fat-storing cells isolated from the rat liver. When seeded at a suitable density, fat-storing cells in primary culture reached confluency in 3 to 4 days and could be transferred and established as cell lines for at least two passages. The typical morphological characteristics of fat-storing cells in vivo were retained in the cells during primary culture. Vitamin A fluorescence was still associated with lipid droplets of cells in culture up to and including the second passage. Investigation of the cytoskeletal structure by indirect immunofluorescence showed the presence of vimentin, actin and tubulin in the cells; no alpha-prekeratin was present. The presence of vimentin suggested a fibroblastic or possible myogenic origin for fat-storing cells. The presence of connective tissue components in fat-storing cells in culture was demonstrated by indirect immunofluorescence. Collagen Types I and IV and laminin were present intracellularly in small granules in fat-storing cells in primary culture and in the first passage. Cells in the fourth passage contained only collagen Type 1. Fibronectin was only aligned extracellularly along the cell membrane, which did not exclude an extracellular source. Rat liver fat-storing cells in culture show a high proliferating capacity. Cell multiplication during prolonged culture was associated with phenotypic transition to a more fibroblastic appearance and gradual disappearance of vitamin A. These results indicate that fat-storing cells may be among the cell types involved in pathological changes observed during development of liver fibrosis.